ArticleNPJ vaccines2025
mRNA-LNP vaccine encoding CDV hemagglutinin confers effective protection in raccoon dogs.
Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Canine distemper virus (CDV) is a highly contagious morbillivirus that causes severe disease in carnivores, with raccoon dogs (Nyctereutes procyonoides) serving as major reservoirs for transmission. To address the limitations of current vaccines-such as virulence reversion, multiple doses, and poor efficacy in raccoon dogs-we developed a novel mRNA-lipid nanoparticle (LNP) vaccine encoding a secreted, tetrameric CDV hemagglutinin (H) protein fused to a signal peptide and Tetrabrachion domain to enhance stability and immunogenicity. The vaccine showed high purity, uniform particle size (~108 nm), and efficient in vivo expression of glycosylated H protein. In BALB/c mice, it induced strong H-specific IgG and increased splenic CD4⁺ T cells, suggesting a Th-skewed immune response. In raccoon dogs, high neutralizing antibody titers were maintained post-immunization, and all vaccinated animals survived lethal CDV challenge, whereas controls showed 100% mortality. Compared with a live-attenuated CDV vaccine, the mRNA-LNP vaccine markedly reduced clinical signs, preserved intestinal integrity, and nearly eliminated viral RNA in mucosal and systemic tissues. This study provides the first evidence that an mRNA-LNP vaccine encoding CDV hemagglutinin can confer complete protection against CDV challenge in raccoon dogs, highlighting its potential for veterinary and wildlife disease prevention.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.